A regulatory role for CD72 expression on B cells and increased soluble CD72 in primary Sjogren’s syndrome

Yuqi Shen†, Yuhua Ma†, Jingyuan Xie1, Li Lin1, Yifan Shi1, Xiao Li1, Pingyan Shen1, Xiaoxia Pan1 and Hong Ren1*

Abstract

Background: CD72, a co-receptor of B cell receptor (BCR), has been reported to have both positive and negative effects on B cell functions in several immunological diseases. The B cell plays an important role in the pathogenesis of primary Sjogren’s syndrome (pSS). However, whether CD72 is involved in the process remains unknown. This study aimed to observe the possible role of CD72 in the pathogenesis of pSS.

Results: A total of 60 cases who fulfilled the American-European Consensus Group (AECG) criteria for the diagnosis of pSS and 61 gender and age-matched healthy controls were recruited in this study. The percentage of CD72+ B cells was 85.31 ± 8.37% in pSS patients and 76.91 ± 8.50% in healthy controls (p < 0.001). The percentage of CD72+ B cells was correlated to serum IgG levels in patients (β = 0.018(0.001–0.036), p = 0.034). The level of serum soluble CD72 was significantly higher in pSS patients than the one in healthy controls (0.41 (0.29) vs 0.07 (0.08) ng/mL, p < 0.001).

Conclusions: The percentage of CD72+ B cells was upregulated in pSS patients and was correlated to the serum IgG level, which revealed the hyperactivity of B cells in this disease. The serum soluble CD72 level was also increased in pSS patients. These results indicated a potential role of CD72 in the pathogenesis of pSS.

Keywords: Primary Sjogren’s syndrome, CD72 expression on B cell, Serum soluble CD72 level, Serum IgG level

Background

Primary Sjogren’s syndrome (pSS) is a systemic autoimmune epithelitis characterized by heterogenous clinical manifestations, ranging from xerostomia and xerophthalmia to non-Hodgkin’s lymphoma (NHL) [1, 2]. It affects 0.01–0.1% of the population and has a major impact on patients’ quality of life [3–5]. B cell hyperactivity, reflected by increased serum levels of IgG, IgM, rheumatoid factor (RF) and the presence of anti-SSA and anti-SSB autoantibodies, is a common finding in SS. Hence, B cells play an important role in the pathogenesis of primary Sjogren’s syndrome (pSS) [6].

CD72 is a coreceptor of B cell receptor (BCR), which is expressed on all B cells starting at the pre-B cell stage, but its expression decreases significantly during differentiation into plasma cells. It has a conserved intracellular domain, which contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) that binds SHP-1, a tyrosine phosphatase, and an ITIM-like motif that binds Grb2, an adaptor protein required to activate the Ras pathway [7]. The association between SHP-1 and CD72 forms the basis of a negative signaling function for CD72 [8, 9]. The complex formed by CD72 and Grb2 is a major positive regulator of BCR signaling [10, 11]. CD100, constitutively expressed on T cells, is the natural ligand of CD72 [12, 13]. CD72 is known to play an important role in various B cell processes, including proliferation, apoptosis and differentiation. CD40-induced B cell proliferation was enhanced by ligation of CD72 with...
CD100, and antigen-mediated B cells proliferation was also enhanced by CD72 ligation [12, 14]. However, other studies revealed that B cells from CD72-deficient mice exhibited increased B cell proliferation in response to BCR ligation [15, 16]. Similarly, CD72 was found to play opposing effects on B cell survival in different studies [8, 16–18]. As for its differentiation, CD72 positively regulates the transition of pre-B cells to mature B cells, and has a mild negative effect on B-1 cell development [15, 19]. Hence, CD72 has both positive and negative effects on B cell functions.

CD72 has been studied in several immunological diseases. The expression of CD72 on B cells decreased while the serum soluble CD72(sCD72) level increased in SLE patients as compared to health controls [20, 21]. Moreover, the expression of CD72 on B cells also decreased in patients with multiple sclerosis [22, 23]. In contrast, the expression of CD72 on B cells was upregulated in pSS patient in the study by Smith et al. [24]. However, the study only included 15 pSS patients, and the expression of soluble CD72 in pSS patients has not been explored till date.

In this study, we investigated the expression of CD72 on B cells as well as the serum soluble CD72 level in pSS patients. Our findings suggest that expression of CD72 is correlated to the hyperactivity of B cells and plays a role in the pathogenesis of primary Sjogren’s syndrome.

**Results**

**CD72 expression on B cells**

According to our results, the mean fluorescence intensity (MFI) of CD72 on CD19+ B cells was slightly but not statistically higher in pSS patients compared to that in healthy controls (11,421.86 ± 3725.03 vs 10,350.81 ± 1451.95, p = 0.14). However, the percentage of CD72+ B cells was significantly increased in patients than in controls (85.31 ± 8.37% vs 76.91 ± 8.50%, p < 0.001) (Fig. 1).

**Association between CD72 expression on B cells and serum indicators**

The result of Pearson’s correlation coefficient showed that the percentage of CD72+ B cells was positively correlated with the serum IgG level (p = 0.03, r = 0.4) (Fig. 2a). The correlation persisted after adjusting for age and gender with linear regression analyses (backward) (β = 0.018(0.001–0.036), p = 0.034). However, a significant difference of the percentage of CD72+ B cells was not found between patients with positive anti-SSA antibodies and those with negative antibodies (Fig. 2b).

**Expression of serum CD72**

As shown in Fig. 3, the serum soluble CD72 level was significantly higher in pSS patients than in healthy controls [0.41(0.29) vs 0.07(0.08) ng/mL, p < 0.001]. However, there was no significant correlation between the sCD72 levels and the serum levels of anti-SSA antibodies [anti-SSA+ vs anti-SSA−: 0.39 (0.29) ng/mL vs 0.42 (0.3) ng/mL, p = 0.3] as well as IgG (p = 0.71) (Fig. 4a and b).

**Discussion**

The involvement of B lymphocytes has been increasingly recognized in the occurrence of primary Sjogren’s Syndrome (pSS) [6]. And CD72, being a coreceptor of B cell receptor (BCR), has been reported to be an important regulator in the pathogenesis of several autoimmune diseases [20–23, 25]. However, the role of CD72 in pSS has been rarely studied [24]. Here, we examined the expression of CD72 on B cells, and for the first time, the level of the soluble form of CD72 in pSS patients. Our findings suggest that expression of CD72 is correlated to the hyperactivity of B cells and plays a role in the pathogenesis of pSS.

Several studies have reported the aberrant expression of CD72 on B cells in autoimmune diseases and suggested that it has both positive and negative effects on B cell development and function. In SLE patients, the lower expression of CD72 on B cells was inversely associated with patients’ disease activity (SLEDAI) and correlated with the presence of lupus nephritis, anti-dsDNA antibodies and low levels of complement [20]. In multiple sclerosis, the expression of CD72 decreased along with an increase in expression of its ligand CD100 on T cells and abnormal levels of several inflammatory factors [22, 23].
Conversely, CD72 expression was upregulated on CD19+CD27+ memory B cells in immune thrombocytopenia (ITP), and was associated with platelet count and anti-platelet antibodies [25]. As a negative regulator of BCR signals, once B cells are stimulated by antigens, CD72 molecules would be recruited by BCR signals to the kinase-rich BCR complex and be phosphorylated. The phosphorylated CD72 recruits SHP-1 by its ITIM and the CD72-associated SHP-1, in turn, negatively regulates BCR signals. CD72-bound Grb2 can reduce the strength of the negative signals transmitted by CD72 associated SHP-1. Moreover, it has been proved that ligation of CD72 by CD100 can dissociate SHP-1 from CD72. However, CD72 acts as a positive regulator of B cell activation not only by dissociating SHP-1 from CD72 but also by a BCR-independent pathway through activating signals such as btk or mitogen-activated protein kinases (MAPK) by associating with CD19 [7].

Our data demonstrated that the expression of CD72 on CD19+ B cells was upregulated in pSS patients as compared to healthy controls, which was consistent with the findings of Smith et al. [24]. Furthermore, we found that CD72 expression on B cells was closely correlated with patients’ serum IgG level. These observations suggested that CD72 positively regulates B cell functions in pSS and its expression on CD19+ B cells is associated with the hyperactivity of B cells in pSS patients.

Moreover, we assessed the level of serum soluble CD72 in pSS patients for the first time. A previous study found that sCD72 was higher in SLE patients and its level significantly correlated to SLEDAI, the presence of aCL, dsDNA antibodies and lupus nephritis [21]. Similarly, our data showed that sCD72 also increased in pSS patients. According to Zahava Vadasz, et al., such upregulation of sCD72 might be due to the dysregulation of B cells and more intense shedding of CD72 from the membrane of B cells in response to stimulation. Hence, the increase of sCD72 in patients’ serum indicates the hyperactivity of B cells [21].

Conclusions

In summary, this study found that the expression of CD72 on CD19+ B cells was upregulated in pSS patients and was closely correlated with patients’ serum IgG levels, which suggests that CD72 positively regulates B cell functions in pSS patients. For the first time, this study found that the serum soluble CD72 was also increased in pSS patients which might be attributed to the hyperactivity of B cells. Future studies should be designed to investigate the specific role of CD72 in the pathogenesis of pSS.
Methods

Patients

A total of 60 pSS patients from the Department of Nephrology of Ruijin Hospital and 61 gender and age-matched healthy controls (females: 55 vs 56, \( p = 1 \); mean age: 46.9 ± 13.16 vs 43.25 ± 11.22 years old, \( p = 0.46 \)) were recruited in this study. All patients fulfilled the American-European Consensus Group (AECG) criteria for the diagnosis of pSS. Specific inclusion criteria are as follows: (1) ocular symptom; (2) oral symptoms; (3) positive antibodies to SSA or SSB antigens, or both; (4) Unstimulated whole salivary flow \( \leq 1.5 \) ml/15 min; (5) Schirmer’s test ≤ 5 mm per 5 min; (6) ≥ 50 inflammatory cells/4 mm\(^2\) of Minor labial salivary gland on biopsy. Patients who have the presence of any 4 of 6 above items (either item 3 or 6 was positive) or 3 of the latter four items were diagnosed as pSS. Exclusion criteria include active hepatitis C virus infection on polymerase-chain-reaction assay, acquired immunodeficiency disease, radiotherapy of head and neck, graft versus host disease, receipt of anticholinergic drugs, history of lymphoma, IgG4-related disease, sarcoidosis and another well-defined connective tissue disease.

Salivary gland biopsies were performed in all patients and typical performances of Sjogren’s syndrome were found in 59 (98.33%) samples. The unstimulated whole salivary flow test was assessed in 42 cases, and 40 (95.24%) of which met the criteria for SS. The Schirmer’s test was conducted in 28 cases, and 25 (89.29%) cases fulfilled the criteria for SS. The anti-SSA antibodies were positive in 41 of 60 (68.33%) patients, and the anti-SSB antibodies were positive in 32 (53.33%) patients. The mean serum IgG level, an indicator revealing B cells activity, was 2039.47 ± 753.85 mg/dL in patients (Table 1). Fresh heparinized whole blood samples were available from 28 patients and 31 controls for FCM,

Table 1 Characteristics of pSS patients and healthy controls

|                          | pSS     | control | \( p \) value |
|--------------------------|---------|---------|--------------|
| n                        | 60      | 61      | 1            |
| Female (n)               | 55      | 56      |              |
| Age (Y)                  | 46.9 ± 13.16 | 43.25 ± 11.22 | 0.46        |
| Anti-SSA antibodies+ (n (%)) | 41 (68.33) |          |              |
| Anti-SSB antibodies+ (n (%)) | 32 (53.33) |          |              |
| IgG (mg/dl)              | 2039.47 ± 753.85 |        |              |
| Unstimulated whole salivary flow\( \leq 1.5 \) ml/15 min (n (%)) | 40 (95.24) |          |              |
| Schirmer’s test ≤ 5 mm per 5 min (n (%)) | 25 (89.29%) |          |              |
| ≥ 50 inflammatory cells/4 mm\(^2\) of Minor labial salivary gland on biopsy (n (%)) | 59 (98.33) |          |              |

pSS Primary Sjogren’s syndrome, IgG Immunoglobulin G
while serum sCD72 levels were tested in 47 patients and 30 controls. No patient received any immuno-suppressive therapy before blood samples were drawn.

This study was approved by the Ruijin Hospital Ethics Committee at the Shanghai Jiao Tong University School of Medicine (2010 No. 29) in agreement with the Declaration of Helsinki. All subjects provided written informed consent.

**Flow cytometry (FCM)**

20 μL human anti-CD19 PE (BD, US) and anti-CD72 FITC (BD, US) antibodies were added to 100 μL fresh heparinized whole blood samples from pSS patients or controls, and incubated for 30 min at room temperature in the dark. Then 4 ml 1x red blood cell (RBC) lysis buffer was added and mixed thoroughly. After incubation for 15 min, the samples were centrifuged at 1500 rpm for 20 min at 4 °C. The supernatant was discarded and the precipitate was washed with phosphate buffered saline (PBS). Then, 200 μL PBS was added and mixed thoroughly with the precipitate, and the samples were analyzed by FACS (Beckman Coulter). The representative presentation of the Flow Cytometer tests was shown in Fig. 5.

**Analysis of soluble CD72**

Serum levels of sCD72 were tested by commercial ELISA kits (MBS2023047, MyBiosource, USA), according to the manufacturer’s instructions.

**Statistical analyses**

Statistical analyses were performed with IBM SPSS Statistics version 21.0. Normally distributed, non-normally distributed, and categorical variables were presented as the mean ± SD, median (interquartile ranges, IQRs), or frequency (percentage), respectively. For comparing variables between different groups, t-test and non-parametric tests were used according to the distributional features of the data.

Pearson’s correlation coefficient and linear regression analyses were conducted to detect associations between CD72 expression and clinical parameters.

**Abbreviations**

BCR: B cell receptor; pSS: Primary Sjogren’s syndrome; AECG: American-European Consensus Group; IgG: Immunoglobulin G; NHL: Non-Hodgkin’s lymphoma; IgM: Immunoglobulin M; RF: Rheumatoid factor; ITIM: Tyrosine-based inhibitory motif; FCM: Flow cytometry; ELISA: Enzyme-linked immunosorbent assay; MAPK: Mitogen-activated protein kinases; MFI: Mean fluorescence intensity; RBC: Red blood cell; SLEDAI: Systemic Lupus Erythematosus Disease Activity

**Acknowledgements**

Not applicable.

**Authors’ contributions**

HR and JYX designed the study and revised the manuscript; YQS performed experiments, analyzed the data and drafted the manuscript; YHM helped interpret the data; LL and YFS helped to do experiments; XL, PYS and XXP helped to collect samples. All authors have read and approved the manuscript.

**Funding**

This work was supported by grants from the National Key Research and Development Program of China (2016YFC0904100) and the Science and Technology Innovation Action Plan of Shanghai Science and Technology Committee (No.17441902200). The funder, JYX, designed the study and revised the manuscript.

**Availability of data and materials**

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This study was approved by the Ruijin Hospital Ethics Committee at the Shanghai Jiao Tong University School of Medicine (2010 No. 29) in agreement with the Declaration of Helsinki. All subjects provided written informed consent.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Nephrology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai 200025, China.
2Department of Nephrology, Traditional Chinese Medicine Hospital of KunShan, Suzhou, China.

Received: 3 December 2019 Accepted: 6 April 2020
Published online: 19 April 2020

References
1. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weissman MH. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 2002;61:594–8.
2. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888–92.
3. Ramos-Casals M, Brito-Zeron P, Sisoo-Almirall A, Bosch X. Primary Sjögren’s syndrome. Br Med J. 2012;344:e821. https://doi.org/10.1136/bmj.e821.
4. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2014;74:1983–9. https://doi.org/10.1136/annrheumdis-2014-205375.
5. Meijer JM, Meiners PM, Huddleston Slater JR, Spijkervet FKL, Kallenberg CGM, Vissink A, Bootma H. Health-related quality of life, employment and disability in patients with Sjögren’s syndrome. Rheumatology (Oxford). 2009;48:1077–82. https://doi.org/10.1093/rheumatology/kep141.
6. Carubbi F, Cipriani P, Marelli A, Benedetto P, Ruscitti P, Bersardi R, Pantano I, Lakouk V, Alvaro S, Alunno A, Marano A, Ciccia F, Gerli R, Trisolo G, Giacometti R. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15(R72). https://doi.org/10.1186/ar4359.
7. Wu H-J, Bondada S. CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function. J Clin Immunol. 2009;29:12–21. https://doi.org/10.1007/s10875-008-9264-6.
8. Wu Y, Nadler MJ, Brennan LA, Gish GD, Timms JF, Fusaki N, Jongstra-Bilen J, Tada N, Lawson T, Wither J, Heid BG, Hozumi N. The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol. 1998;8:1009–14.
9. Adachi T, Flaswinkel H, Yakura H, Keth M, Tsuabata T. The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol. 1998;160:4662–5.
10. Fusaki N, Tomita S, Wu Y, Okamoto N, Goitsuka R, Kitamura D, Hozumi N. BLNK is associated with the CD72/SHP-1/Grb2 complex in the WEHI231 cell line after membrane IgM cross-linking. Eur J Immunol. 2000;30:1236–30.
11. Campbell KS. Signal transduction from the B cell antigen-receptor. Curr Opin Immunol. 1999;11:256–64.
12. Kumanogoh A, Watanabe C, Ichida J, Wang X, Shi W, Araki H, Hirata I, Iwahori K, Uchida J, Yasui T, Matsumoto M, Yoshida K, Kikutani H. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunol. 2000;10:633–42.
13. Ishida I, Kumanogoh A, Suzuki K, Akahani S, Noda K, Kikutani H. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int Immunol. 2003;15:1027–34.
14. Snow EC, Mond JJ, Subbarao B. Enhancement by monoclonal anti-Ly4.2 antibody of antigen-specific B lymphocyte expansion stimulated by TNF-α, Ficol and T lymphocyte-derived factors. J Immunol. 1986;137:1793–6.
15. Pan C, Baumgart N, Parnes JR. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity. 1999;11:495–506.
16. Li DH, Tung JW, Tanner HI, Snow AL, Yukinari T, Ngermanneepothong R, Martinez OM, Parnes JR. CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes. J Immunol. 2006;176:3521–8.
17. Nomura T, Han H, Howard MC, Yahiga Y, Yakura H, Hongo T, Tsuabata T. Antigen receptor-mediated B cell death is blocked by signaling via CD72 or treatment with dexamethasone and is defective in autoimmune-prone mice. Int Immunol. 1996;8:867–75.
18. Baba T, Fusaki N, Aoyama A, Li DH, Okamura RM, Parnes JR, Hozumi N. Dual regulation of BCR-mediated growth inhibition signaling by CD72. Eur J Immunol. 2005;35:1634–42. https://doi.org/10.1002/eji.200425775.
19. Shi W, Kumanogoh A, Watanabe C, Ichida J, Wang X, Yatsi T, Yukawa K, Ikawa M, Okabe M, Parnes JR, Yoshida K, Kikutani H. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunol. 2000;10:633–42.
20. Vadasz Z, Haj T, Balbír A, Peri R, Rosner I, Slobodin G, Kessel A, Toubi E. A regulatory role for CD72 expression on B cells in systemic lupus erythematosus. Semin Arthritis Rheum. 2014;43:767–71. https://doi.org/10.1016/j.semarthritis.2013.11.010.
21. Vadasz Z, Goldenberg Y, Halazk Y, Rosner I, Valesiri G, Conti F, Perricone C, Shhoezer Z, Bezalel SR, Tzoufas AG, Levin NA, Shoenfeld Y, Toubi E. Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis. Clin Immunol. 2016;164:114–8. https://doi.org/10.1016/j.clim.2016.02.004.
22. Kukлина EM, Baidina TV, Danchenko YF, Nekraosva IV, Semaforin Sema4D in the immune system in multiple sclerosis. Bull Exp Biol Med. 2014;157:234–7. https://doi.org/10.1007/s10517-014-2533-x.
23. Kukлина EM, Nekraosva IV, Baidina TV, Danchenko YF. The role of the sema4D/CD72-dependent signal in the regulation of B-cell activity in multiple sclerosis. Dold Biol Sci. 2014;45:316–8. https://doi.org/10.1134/S01249661405007X.
24. Smith AI, Gordon TP, Macardie PJ. Increased expression of the B-cell regulator molecule CD72 in primary Sjögren’s syndrome. Tissue Antigens. 2004;63:255–6. https://doi.org/10.1111/j.1399-0039.2004.00187.x.
25. Lyu M, Hao Y, Li Y, Lyu C, Liu W, Li H, Xue F, Liu X, Yang R. Upregulation of CD72 expression on CD19+CD27+ memory B cells by CD40L in primary immune thrombocytopenia. Br J Haematol. 2017;178:308–18. https://doi.org/10.1111/bjh.14671.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions